AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00435435
Drug: Disulfiram
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00435435
Drug: Naltexone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02081625
Drug: NS-065/NCNP-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NS-065/NCNP-01 for Infusion is packaged as 25 mg/mL in phosphate buffered saline with 1 mL per vial. Study dosages will be infused over a 1 hour period with Normal saline as follows:~Cohort 1: 1.25mg/kg once weekly for 12 weeks; Cohort 2: 5.0mg/kg once weekly for 12 weeks; Cohort 3: 20.0mg/kg once weekly for 12 weeks
Trial: NCT02612480
Drug: Acetylsalicylic acid lysinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 day treatment of acetylsalicyclic acid 1d80mg after a loading dose of 160mg
Trial: NCT02612480
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 day treatment with placebo
Trial: NCT03651102
Drug: Thalidomide and Hydroxyurea
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dosage: Thalidomide 1-4mg/kg/day, Hydroxyurea 10-20mg/kg/day
Trial: NCT00638456
Drug: placebo plus Prevacid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is taken daily for three months. In addition, Prevacid is taken twice daily for three months.
Trial: NCT05085106
Drug: Placebo eye drop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo eye drop: 0.0%, 1 drop will be instilled as instructed over one day in single-dose study; 0.0%, 1 drop per time, four times each day and for seven days totally in multiple-dose study.
Trial: NCT04874142
Drug: YYC506-A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single administration
Trial: NCT04601103
Drug: No SLS toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toothpaste no Sodium Lauryl Sulfate
Trial: NCT04601103
Drug: Medium SLS toothpaste
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less than or equal to X ppm Sodium Lauryl Sulfate
Trial: NCT00993759
Drug: 3804-250A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.2 ml applied topically after hand washing and at least every 3 hours while awake.
Trial: NCT00578344
Drug: Cyclophosphamide and MESNA
RxNorm normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Day -5 through Day -2; Cyclophosphamide 50 mg/kg + MESNA.
Trial: NCT02165202
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to the placebo arm will receive oral placebo capsules prior to injection of saline solution (0.9%NaCI). Participants will be observed while taking the study product by site staff on approximately six occasions during the first two weeks of the oral run-in at Week 0 (Enrollment), at Week 2 (Oral Run-in Safety Visit), and on four separate DOT visits between Weeks 0 and 2. Cervicovaginal and rectal fluid will be collected for PK studies at a single follow-up visit.
Trial: NCT01836523
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
Trial: NCT03052517
Drug: QAW039 450 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet of QAW039 450 mg once daily
Trial: NCT03052517
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet of Placebo once daily
Trial: NCT01236898
Drug: NPC-09
RxNorm normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPC-09 tablet NPC-09 contains 50mg or 100mg N-acetylneuraminic acid (anhydride)
Trial: NCT01303471
Drug: opioid (remifentanyl)
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of remifentanyl (opioid) will be started at different levels for each group of the randomized study : 0 ng/ml (group 0), 1 ng/ml (group 1), 3 ng/ml (group 3) or 4 ng/ml (group 4)
Trial: NCT00689637
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules qd, 12 days
Trial: NCT00973414
Drug: Ringer's Lactate
RxNorm normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's Lactate 8 ml/kg was given intravenously before or after CSEA in cesarean section
Trial: NCT01993459
Drug: NaCl (sodium chloride) 0,9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We will administer NaCl (sodium chloride) 0,9% 3ml intravenously once pre-operatively to patients just before they undergo surgery
Trial: NCT03520595
Drug: Arnica 200 drug 3 pills,3 times daily for 3 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CLP with ostectomy done in patients whose biologic width and crown height is insufficient
Trial: NCT03520595
Drug: Diclofenac Sodium 50mg twice daily
RxNorm normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: CLP with ostectomy done in patients whose biologic width and crown height is insufficient
Trial: NCT01903954
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally b.i.d.
Trial: NCT01758978
Drug: a 60 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 30-mg tablets (Treatment A) or one 60-mg tablet (Treatment B).
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will receive 1 treatment during each administration period. Subjects will receive each of the 2 treatments once. There will be a minimum 14-day washout period between the 2 administrations of study drug. Treatments will be orally administered to subjects, while they are seated, at approximately 0800 (±2 hours) on the 1st day of each administration period.
Trial: NCT01907061
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo or NAC will be given
Trial: NCT01351675
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, once daily
Trial: NCT00813709
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose matching placebo will be administered subcutaneously twice weekly. Placebo is supplied as a transparent, sterile solution for injection in pre-filled syringes matching the RNF pre-filled syringes, each containing 0.5 milliliter (mL).
Trial: NCT00603798
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 3 weeks of daily treatment followed by 3 weeks of no treatment, and the second treatment cycle consisted of an additional 3 weeks of daily treatment followed by 8 weeks of no treatment.
Trial: NCT06318052
Drug: Gynomunal gel treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hormone/free, vaginal moisturizing gel for women with vaginal dryness
Trial: NCT03299686
Drug: CJM112
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg CJM112 (Study treatment) s.c. injection received per week for the first 4 weeks, followed by once every two weeks up to Week 12 (Day 85) + standard of care treatment.
Trial: NCT03745222
Drug: Concurrent chemoradiotherapy (cCRT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy options include carboplatin/paclitaxel and cisplatin/etoposide per standard of care. Radiotherapy will also be given concurrently with chemotherapy.
Trial: NCT03098940
Drug: Chewing Gum
RxNorm normalized name: Chewing Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the study healthy subjects will receive single doses of the various strengths of dronabinol
Trial: NCT01361269
Drug: Fosmidomycin and clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study drugs will be co-administered under supervision by a study physician or nurse in doses of fosmidomycin 30mg/kg/dose + clindamycin 10mg/kg/dose twice daily for three days (total daily dose fosmidomycin 60mg/kg, clindamycin 20mg/kg).
Trial: NCT05002517
Drug: Methylprednisolone group
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone belongs to a group of medicines called corticosteroids (it works at the cellular level by reducing the production of substances that cause inflammation or allergy).
Trial: NCT00206557
Drug: Estradiol/dyhydroprogestrone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04975022
Drug: N11005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral insulin N11005, 300IU, p.o.
Trial: NCT01945749
Drug: Intraarticular saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml isotonic saline mixed with 4 ml Lidocain (10 mg/ml) without adrenalin. Injections are done ultrasound guided
Trial: NCT00365586
Drug: Ketoprofen Topical Patch , 20%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01702675
Drug: ACH15 50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACH15 50mg capsule
Trial: NCT01702675
Drug: ACH15 250 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACH15 250mg capsule
Trial: NCT01702675
Drug: ACH15 500mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACH15 500 mg capsule
Trial: NCT01702675
Drug: ACH15 - 1000mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACH15 500mg capsule - two 500mg capsules in single dose
Trial: NCT01702675
Drug: ACH15 - 2000mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACH15 500mg capsule (four 500mg capsules in one dose)
Trial: NCT01702675
Drug: ACH15 - 500mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACH15 - 500mg twice a day for 7 days
Trial: NCT01702675
Drug: Placebo 250 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule manufactured to mimic ACH15 250 mg capsule
Trial: NCT01702675
Drug: Placebo 500mg
RxNorm normalized name: placebo 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule manufactured to mimic ACH15 500 mg capsule
Trial: NCT01702675
Drug: Placebo 1000mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule manufactured to mimic ACH15 500 mg capsule Placebo 500mg (two 500 mg capsules in one dose)
Trial: NCT01702675
Drug: Placebo 2000mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule manufactured to mimic ACH15 500 mg capsule Placebo 500mg (four 500 mg capsules in one dose)
Trial: NCT01702675
Drug: Placebo 500mg
RxNorm normalized name: placebo 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule manufactured to mimic ACH15 500 mg capsule Placebo 500mg (500 mg capsules twice a day for 7 days)
Trial: NCT00654992
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 IU/kg of normal saline intravenously before surgery
Trial: NCT00785317
Drug: Angemin vs Activelle
RxNorm normalized name: estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg of oral oestradiol (E2) in continuous combination with 2 mg of DRSP or 1 mg of oral E2 in continuous combination with 0.5 mg of NETA during six months.
Trial: NCT00499863
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch
Trial: NCT03463707
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to Investigational product BP101, nasal spray
Trial: NCT02409381
Drug: Motore
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250 mg
Trial: NCT02691728
Drug: LDV/SOF FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00420992
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules, bid
Trial: NCT01119430
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Similar pill as active comparator twice a day
Trial: NCT04159649
Drug: Gonadotropins
RxNorm normalized name: GONADOTROPINS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotropins without letrozol in fixed Gn RH antagonist IVF protocol
Trial: NCT02415699
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02415699
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03962725
Drug: Neuromuscular Blocking Agents
RxNorm normalized name: NEUROMUSCULAR BLOCKING AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of non depolarizing neuromuscular blocking agents for maintenance of general anesthesia.
Trial: NCT03962725
Drug: Anesthetic Adjuncts
RxNorm normalized name: ANESTHETIC ADJUNCTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of deeper plane of inhaled anesthetics or adjuncts (opioids, propofol, dexmedetomidine or ketamine for maintenance of general anesthesia.
Trial: NCT01565369
Drug: florbetapir F 18
RxNorm normalized name: Florbetapir F 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV injection, 370MBq (10mCi), single dose
Trial: NCT00591201
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo -powder diluted in 250 ml of isotonic solution of sodium chloride- will be administered on weeks 0, 2 and 6.
Trial: NCT01691521
Drug: IV Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (placebo) will be administered IV every 4 weeks with the last dose at Week 28
Trial: NCT01691521
Drug: SC Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (placebo) will be administered SC every 4 weeks with the last dose at Week 28
Trial: NCT00058201
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00793624
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for comparison with Olodaterol (BI 1744) on safety and efficacy in COPD patients
Trial: NCT00793624
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for comparison Formoterolon safety and efficacy in COPD patients
Trial: NCT00774527
Drug: Cyclophosphamide-fludarabine-anti thymocyte globulin
RxNorm normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Cyclophosphamide 50 mg/kg in D5W 200 ml i.v. over 1-2 hours on days -5 to -2 by pump through a central venous catheter.~* Fludarabine 30 mg/m2 will be infused intravenously over 30 minutes in D5W 100 ml for 5 consecutive days (days -6 to -2).~* Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2.
Trial: NCT03064854
Drug: PDR001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powder for solution for infusion
Trial: NCT00058201
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02343003
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delivery of corticosteroid into knee by injection with needle to reduce knee pain
Trial: NCT00500721
Drug: Desipramine
RxNorm normalized name: Desipramine
DrugBank: Desipramine (DB01151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Period 1: Single oral dose of desipramine (50 mg) on day 1. No test article administration on days 2 to 6.~Period 2: Multiple oral doses of HCV-796 (500 mg) every 12 hours on days 1 to 9.~Period 3: Multiple oral doses of HCV-796 (500 mg) every 12 hours on days 10 to 14 and a single oral dose of desipramine (50 mg) on day 10.
Trial: NCT03756727
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in Ascorbic acid group received 2g of intravenous Ascorbic acid at the night before surgery, during the surgery and five days after surgery (once a day).
Trial: NCT04015076
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to Match
Trial: NCT03370575
Drug: the second-generation non-ionic monomer contrast
RxNorm normalized name: NON-IONIC CONTRAST MEDIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hysterosalpingography using the second-generation non-ionic monomer contrast
Trial: NCT02693821
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 300 mg per day, orally during 30 days
Trial: NCT01939886
Drug: Artemether-lumefantrine combination
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03301597
Drug: Standard of Care (SOC) chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The SOC chemotherapy regimen for each patient will be determined by local PI. Regimen must be a standard AML regimen that will result in moderate to severe myelosuppression and have curative intent.
Trial: NCT00177281
Drug: S CKD602
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02712125
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo vaginal tablets once daily until delivery
Trial: NCT00466102
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet of 5 mg, 2 tablets (10 mg) are taken once daily during study therapy
Trial: NCT00466102
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets are taken once daily during study therapy
Trial: NCT01632904
Drug: HU-placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All placebo will be self-administered, and dosing will be the same as with the blinded dose.~When adjustments are made to the ruxolitinib dose, the dose of HU-placebo will be adjusted concurrently.
Trial: NCT01045083
Drug: RO4917523
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral single dose
Trial: NCT01045083
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral single dose
Trial: NCT04721704
Drug: Clarithromycin+ Amoxicillin + Omeprazole
RxNorm normalized name: AMOXICILLIN/OMEPRAZOLE/RIFABUTIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Group A: Amoxicillin AMO + Clarithromycin CLA + Proton pump inhibitor PPI will be given to children
Trial: NCT04283292
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream that is applied once topically
Trial: NCT03582605
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: see previous descriptions
Trial: NCT00427206
Drug: acetaminophen (4g/day)
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00427206
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02059434
Drug: LAS190792 Dose 1
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02059434
Drug: LAS190792 Dose 2
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02059434
Drug: LAS190792 Dose 3
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02059434
Drug: LAS190792 Dose 4
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02059434
Drug: LAS190792 Dose 5
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02059434
Drug: LAS190792 Dose 6
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02059434
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01190995
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient will be enrolled into the study only after an informed written consent has been obtained from either of the parent/caregiver. At the beginning of each potentially painful procedure namely, venepuncture, venous and arterial cannulation, heel lance,orogastric tube insertion, suprapubic aspiration of urine and any other skin breaking procedure,0.5ml of solution marked with patients serial number will be administered by a prefilled syringe to the patient on the anterior aspect of the tongue , avoiding spillage , by the personnel carrying out the procedure
Trial: NCT04240158
Drug: IW-6463
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IW-6463 Tablet
Trial: NCT04240158
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo Tablet
Trial: NCT00118742
Drug: mycophenolate mofetil [CellCept]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-1.5 g orally or intravenously twice daily
Trial: NCT02634034
Drug: A: NK-104-CR 8 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NK-104-CR 8 mg (Controlled Release single 8-mg tablet)
Trial: NCT01668524
Drug: ATS907
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of each of three increasing concentrations
Trial: NCT03635905
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylcellulose placebo capsule
Trial: NCT03191136
Drug: YHD1119 300mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Period 1:a single dose of YHD1119 300mg is administered in fasting condition Period 2:a single dose of YHD1119 300mg is administered in fed condition
Trial: NCT03935152
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsule
Trial: NCT00564447
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: azithromycin topical solution 1% given as a single drop in a single eye
Trial: NCT00402532
Drug: Mycophenolatmofetil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial dosage 2 x 500 mg/d intravenous
Trial: NCT02487771
Drug: Placebo Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of Soybean Oil and Corn Oil, which does not contain any DHA
Trial: NCT00492882
Drug: usual administration of exogenous recombinant FSH
FDA approved: no
EMA approved: no
PMDA approved: no